Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.84 |
| ▸ | LMNA | P02545 | 4/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.78 |
| ▸ | MAPT | P10636 | 4/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.78 |
| ▸ | GSTO1 | P78417 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 6/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.63 |
| ▸ | HTT | P42858 | 3/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | ABL1 | P00519 | 1/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3621177 | 1.00 | PARP1 (0.84) | PARP1LMNASMN1; SMN2MAPTKDM4E | |
| SCHEMBL4747429 | 0.85 | PARP1 (0.78) | PARP1LMNASMN1; SMN2MAPTKDM4E | |
| SCHEMBL4747427 | 0.85 | PARP1 (0.78) | PARP1LMNASMN1; SMN2MAPTKDM4E | |
| SCHEMBL4747433 | 0.85 | PARP1 (0.78) | PARP1LMNASMN1; SMN2MAPTKDM4E | |
| SCHEMBL3607905 | 0.85 | RAB9A (0.60) | PARP1LMNASMN1; SMN2MAPTKDM4E | |
| SCHEMBL3607908 | 0.85 | RAB9A (0.60) | PARP1LMNASMN1; SMN2MAPTKDM4E | |
| SCHEMBL3611730 | 0.84 | PARP1 (0.59) | PARP1LMNASMN1; SMN2MAPTKDM4E | |
| SCHEMBL3611727 | 0.84 | PARP1 (0.59) | PARP1LMNASMN1; SMN2MAPTKDM4E | |
| SCHEMBL16682288 | 0.83 | PARP1 (0.58) | PARP1LMNASMN1; SMN2MAPTKDM4E | |
| SCHEMBL4749672 | 0.81 | PARP1 (0.78) | PARP1LMNASMN1; SMN2MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2010-06-03 | — | — | US | claimed |
| EP-1928848-A2 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | Apogee Biothechnology Corporation (US) | 2008-06-11 | — | — | EP | claimed |
| WO-2007019251-A9 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORP (US) | 2007-04-19 | — | — | WO | claimed |
| WO-2007019251-A2 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-15 | — | — | WO | claimed |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-08 | — | — | US | claimed |
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2012-05-17 | — | — | US | disclosed |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| EP-1928848-A2 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | Apogee Biothechnology Corporation (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007019251-A9 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORP (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007019251-A2 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | SPHK1, SPHK2, S1PR2 | PARP1 942/4885LMNA 1345/4885SMN1; SMN2 2253/4885 |
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | SPHK1, SPHK2, S1PR2 | PARP1 1909/4885LMNA 3037/4885SMN1; SMN2 1209/4885 |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | SPHK1, SPHK2, S1PR2 | PARP1 1009/4885LMNA 1466/4885SMN1; SMN2 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.